Pfiz­er re­leas­es he­mo­phil­ia B PhI­II da­ta in chal­lenge to CSL's Hem­genix

Pfiz­er’s he­mo­phil­ia B gene ther­a­py showed strong re­sults in a Phase III tri­al, sharply re­duc­ing the rate of bleed­ing in pa­tients and dras­ti­cal­ly cut­ting their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER